Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 190.80 -3.04 (-1.57%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 47 48 Next > Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday April 25, 2024 Via Benzinga Why Biogen Stock Leaped Nearly 5% Higher Today April 24, 2024 The company came out swinging with its first set of quarterly earnings for this year. Via The Motley Fool Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why April 24, 2024 Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA... Via Benzinga Exposures Product Safety Biogen (BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 BIIB earnings call for the period ending March 31, 2024. Via The Motley Fool Topics Earnings Exposures Financial Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings April 24, 2024 Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging. Via Benzinga Where Biogen Stands With Analysts April 11, 2024 Via Benzinga Looking Into Biogen's Recent Short Interest April 03, 2024 Via Benzinga Forecasting The Future: 18 Analyst Projections For Biogen March 25, 2024 Via Benzinga Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday? April 24, 2024 Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the... Via Benzinga Topics Bonds Exposures Debt Markets BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024 April 24, 2024 BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? April 24, 2024 Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares? Via Investor's Business Daily Topics Earnings Exposures Financial Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally April 24, 2024 Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session April 09, 2024 Via Benzinga 10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? March 29, 2024 Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... Via Talk Markets Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week April 21, 2024 Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. Via Benzinga Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback March 28, 2024 The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. Via Investor's Business Daily Exposures Product Safety Tuesday Talk: Big-Tech Under Attack March 26, 2024 On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. Via Talk Markets Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich March 25, 2024 Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. Via InvestorPlace European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab March 22, 2024 Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. Via Benzinga Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 21, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 10 Health Care Stocks With Whale Alerts In Today's Session March 20, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session March 19, 2024 Via Benzinga 10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? March 16, 2024 Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... Via Talk Markets Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 14, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers March 08, 2024 February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks... Via Benzinga Topics Economy Exposures Interest Rates Are These 5 Undervalued Stocks Ready to Break Out? March 08, 2024 Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. Via MarketBeat Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision March 08, 2024 The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA... Via Benzinga Exposures Product Safety FDA Delays Decision On Eli Lilly's Alzheimer Drug March 08, 2024 The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab. Via Investor's Business Daily Exposures Product Safety Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers March 06, 2024 Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... Via Benzinga New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy March 06, 2024 From Biogen Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 47 48 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.